422 related articles for article (PubMed ID: 21649448)
1. Assessing QT interval prolongation and its associated risks with antipsychotics.
Nielsen J; Graff C; Kanters JK; Toft E; Taylor D; Meyer JM
CNS Drugs; 2011 Jun; 25(6):473-90. PubMed ID: 21649448
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
3. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
4. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
5. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
6. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.
Polcwiartek C; Sneider B; Graff C; Taylor D; Meyer J; Kanters JK; Nielsen J
Psychopharmacology (Berl); 2015 Sep; 232(18):3297-308. PubMed ID: 26231497
[TBL] [Abstract][Full Text] [Related]
7. [Lengthening of QT interval by antipsychotic drugs].
Haverkamp W; Deuschle M
Nervenarzt; 2006 Mar; 77(3):276, 278-80, 282-4 passim. PubMed ID: 16052325
[TBL] [Abstract][Full Text] [Related]
8. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.
Letsas KP; Efremidis M; Kounas SP; Pappas LK; Gavrielatos G; Alexanian IP; Dimopoulos NP; Filippatos GS; Sideris A; Kardaras F
Clin Res Cardiol; 2009 Apr; 98(4):208-12. PubMed ID: 19031039
[TBL] [Abstract][Full Text] [Related]
10. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians.
Trinkley KE; Page RL; Lien H; Yamanouye K; Tisdale JE
Curr Med Res Opin; 2013 Dec; 29(12):1719-26. PubMed ID: 24020938
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms and risks of electrocardiographic QT interval prolongation when using antipsychotic drugs.
Vieweg WV
J Clin Psychiatry; 2002; 63 Suppl 9():18-24. PubMed ID: 12088172
[TBL] [Abstract][Full Text] [Related]
12. Personalized, intuitive & visual QT-prolongation monitoring using patient-specific QTc threshold with pseudo-coloring and explainable AI.
Alahmadi A; Davies A; Vigo M; Jay C
J Electrocardiol; 2023; 81():218-223. PubMed ID: 37837739
[TBL] [Abstract][Full Text] [Related]
13. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
Hasnain M; Vieweg WV
CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784
[TBL] [Abstract][Full Text] [Related]
14. [Cardiac effects of antipsychotics: mechanism of arrhythmias and sudden cardiac death].
Kecskeméti V
Neuropsychopharmacol Hung; 2004 Mar; 6(1):5-12. PubMed ID: 15125308
[TBL] [Abstract][Full Text] [Related]
15. [Antipsychotic drugs and cardiovascular safety: need for monitoring the QT interval].
Trojak B; Pinoit JM; André D; Bonin B; Gisselmann A
Presse Med; 2006 Apr; 35(4 Pt 2):699-704. PubMed ID: 16614617
[TBL] [Abstract][Full Text] [Related]
16. Twenty-Four-Hour Measures of Heart Rate-Corrected QT Interval, Peak-to-End of the T-Wave, and Peak-to-End of the T-Wave/Corrected QT Interval Ratio During Antipsychotic Treatment.
Tümüklü MN; Tümüklü MM; Nesterenko V; Jayathilake K; Beasley CM; Meltzer HY
J Clin Psychopharmacol; 2019; 39(2):100-107. PubMed ID: 30707117
[TBL] [Abstract][Full Text] [Related]
17. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
[TBL] [Abstract][Full Text] [Related]
19. Incidences, risk factors, and clinical correlates of severe QT prolongation after the use of quetiapine or haloperidol.
Wang CL; Wu VC; Lee CH; Wu CL; Chen HM; Huang YT; Chang SH
Heart Rhythm; 2024 Mar; 21(3):321-328. PubMed ID: 38231170
[TBL] [Abstract][Full Text] [Related]
20. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome.
Darbar D; Kimbrough J; Jawaid A; McCray R; Ritchie MD; Roden DM
J Am Coll Cardiol; 2008 Feb; 51(8):836-42. PubMed ID: 18294569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]